{
  "trial_id": "NCT04082780",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Age",
      "label": "met",
      "evidence": "57-year-old gentleman"
    },
    {
      "criterion": "Cirrhosis on liver biopsy or transient elastography",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Nodular liver on imaging",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Endoscopic or radiological evidence of varices in a patient with chronic liver disease",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Platelet count <150,000/mm3 and AST/ALT ratio >1 in a patient with chronic liver disease",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Women of childbearing age will need to be on accepted birth control for 10 days prior to entering study and 30 days after the end of the last dose of the study drug.",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Cognitive impairment on PHES aggregate score [more than or greater than] -4SD - based on norms published in Allampati et al located at the website www.encephalapp.com17",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Willing and able to participate, provide samples and complete follow-up",
      "label": "met",
      "evidence": "He did have some bulky lymphadenopathy."
    },
    {
      "criterion": "Stable Liver function tests between 2-12 weeks prior to enrollment (can include the values established by at least two samples obtained at least 2 weeks and no more than 8-12 weeks apart) to account for disease related changes in liver enzymes and bilirubin while on study that may otherwise be inappropriately attributed to study drug.",
      "label": "unknown",
      "evidence": ""
    }
  ],
  "exclusion": [
    {
      "criterion": "Unclear diagnosis of cirrhosis (does not meet the criteria outlined above)",
      "label": "not_met",
      "evidence": ""
    },
    {
      "criterion": "Child score >8",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Unable to consent, follow for the study duration",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Normal performance on PHES",
      "label": "not_met",
      "evidence": "He did have some bulky lymphadenopathy."
    },
    {
      "criterion": "Mini-mental status exam<2518",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Recent alcohol abuse (within 3 months)",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Recent illicit drug abuse (within 3 months) except marijuana",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Current use of psychoactive drugs apart from long-standing opioids or stable anti-depressant use.",
      "label": "unknown",
      "evidence": ""
    }
  ],
  "notes": "Patient has a history of CLL and large cell transformation, with bulky lymphadenopathy. He has had multiple treatments, including FCR, PCR, R-CVP, and Campath therapy, but has not achieved significant response.",
  "_meta": {
    "topic_id": "8",
    "trial_id": "NCT04082780",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}